Switching from Duloxetine to Auvelity
When switching from duloxetine to Auvelity, taper duloxetine slowly over 1-2 weeks before initiating Auvelity to minimize discontinuation syndrome risk, then start Auvelity at one tablet (45mg dextromethorphan/105mg bupropion) once daily for 3 days before increasing to twice daily dosing.
Critical Safety Considerations Before Switching
Screen for Contraindications
Before initiating the switch, you must screen for:
- Seizure disorder history (absolute contraindication to Auvelity) 1
- Current or prior bulimia/anorexia nervosa (higher seizure risk with bupropion) 1
- MAOI use within 14 days (contraindicated due to serotonin syndrome risk) 1
- Personal or family history of bipolar disorder, mania, or hypomania 1
- Blood pressure (assess baseline and monitor during treatment) 1
Key Drug Interaction Warning
Critical: Duloxetine is metabolized by CYP2D6, and Auvelity contains bupropion which inhibits CYP2D6 2. However, since you're discontinuing duloxetine, this interaction becomes less relevant. The more important concern is that concomitant use of duloxetine (an SNRI) with dextromethorphan can cause serotonin syndrome 1. This makes proper tapering and washout essential.
Recommended Switching Protocol
Step 1: Taper Duloxetine (1-2 weeks)
SNRIs like duloxetine require slow discontinuation tapering to prevent discontinuation syndrome 2. Discontinuation symptoms can include:
- Dizziness, headache, nausea
- Diaphoresis, irritability
- Paresthesias, anxiety
Tapering schedule (adjust based on patient's current dose and tolerance):
- If on duloxetine 60mg daily: reduce to 30mg daily for 1 week, then discontinue
- If on higher doses: use more gradual reductions over 2 weeks
- Monitor closely for discontinuation symptoms 3
Step 2: Brief Washout Period (Optional but Recommended)
Given the serotonin syndrome risk when combining SNRIs with dextromethorphan 1, consider a 2-3 day washout after the final duloxetine dose before starting Auvelity. While duloxetine has a sufficiently long elimination half-life (approximately 12 hours) 2, this brief period allows for clearance and reduces overlapping serotonergic effects.
Note: This is more conservative than switching between typical antidepressants. The evidence shows immediate switching from SSRIs to duloxetine was well-tolerated 4, but Auvelity's dextromethorphan component creates unique serotonin syndrome concerns 1.
Step 3: Initiate Auvelity
Start Auvelity at one tablet (45mg/105mg) once daily in the morning for 3 days, then increase to one tablet twice daily (at least 8 hours apart) 1.
- Take with or without food
- Swallow whole (do not crush, divide, or chew)
- Maximum: 2 tablets per day
- Do not exceed 2 doses within the same day 1
Monitoring During and After the Switch
Week 1-2 Post-Switch
- Assess for serotonin syndrome symptoms: altered mental status, hypertension, restlessness, myoclonus, hyperthermia, hyperreflexia, diaphoresis, tremor 1
- Monitor for suicidal thoughts/behaviors (especially in patients ≤24 years old) 1
- Check blood pressure (Auvelity can increase BP) 1
- Assess for activation symptoms: agitation, anxiety, insomnia 1
Weeks 2-6
- Continue monitoring therapeutic response using standardized scales (e.g., MADRS, PHQ-9)
- Significant improvement may occur as early as week 1-2 with Auvelity 5, 6
- Assess for common adverse effects: dizziness (16%), headache (8%), diarrhea (7%), somnolence (7%), dry mouth (6%), sexual dysfunction (6%), hyperhidrosis (5%) 1
Week 6-8
- If inadequate response by 6-8 weeks, modify treatment 7
- Remission rates with Auvelity at week 6 were 46.5% vs 16.2% with bupropion alone 5
Special Populations Requiring Dose Adjustment
Reduce Auvelity to once daily dosing in:
- Moderate renal impairment (eGFR 30-59 mL/min/1.73m²) 1
- Concomitant strong CYP2D6 inhibitors (though duloxetine will be discontinued) 1
- Known CYP2D6 poor metabolizers 1
Common Pitfalls to Avoid
Abrupt duloxetine discontinuation: Always taper to minimize discontinuation syndrome 2
Ignoring seizure risk factors: Bupropion lowers seizure threshold. Avoid in patients with eating disorders, seizure history, or abrupt benzodiazepine/alcohol discontinuation 1
Missing serotonin syndrome warning signs: The combination of residual duloxetine effects with dextromethorphan creates real risk 1
Inadequate blood pressure monitoring: Both duloxetine and Auvelity can affect blood pressure 2, 1
Overlooking activation symptoms: Monitor for anxiety, agitation, insomnia, especially in first 1-2 weeks 1
Advantages of This Switch
Auvelity offers several potential benefits over duloxetine:
- Faster onset of action: Significant improvement as early as week 1-2 vs typical 4-6 weeks 5, 6
- Different mechanism: NMDA receptor antagonism and sigma-1 receptor agonism vs SNRI mechanism 5, 8
- Lower sexual dysfunction risk: Bupropion component associated with lower sexual side effects compared to SNRIs 7
- No weight gain: Unlike many antidepressants 5
The evidence supporting this switch strategy prioritizes patient safety through gradual duloxetine taper while recognizing Auvelity's unique pharmacology requires careful attention to serotonin syndrome risk during the transition period.